UCSF Brain Tumor Center Clinical Trials
Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors.
Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors.
This study will enroll children and young adults (between the ages of 3 to 21 years old) with newly diagnosed Diffuse Midline Gliomas (DMGs, HLA-A*0201 positive and H3.3K27M positive).
This phase II clinical trial will evaluate the efficacy and side effects of larotrectinib in treating patients with previously untreated TRK fusion solid tumors (including central nervous system (CNS) tumors) and relapsed TRK fusion acute leukemia.